**Specific Changes:** Expand the “Criteria for Further Risk Evaluation for High-Risk Syndromes” on page GAST-D1 to include syndromes other than Hereditary Diffuse Gastric Cancer (HDGC) by adding bullet points for patients with:

- Gastric cancer and a personal or family history of cancers associated with Lynch syndrome (colorectal, endometrial, small bowel, or urinary tract).
- Gastric cancer and a personal or family history of gastrointestinal polyposis including adenomatous, juvenile or other types of polyps

**FDA Clearance:** Not applicable.

**Rationale:** The current risk evaluation criteria on page GAST-D1 appear to be focused almost exclusively on HDGC, without accounting for the association of gastric cancer with the extensive list of additional hereditary cancer syndromes described subsequently on pages GAST-D2 to GAST-D6.

**Citations:**


Sincerely,

Johnathan Lancaster, MD, PhD
Chief Medical Officer, Myriad Genetic Laboratories Inc.